Cargando…
The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells
INTRODUCTION: Recent studies have suggested that the VEGF inhibitors, Ranibizumab and Aflibercept may be associated with an excess of cardiovascular events, potentially driven by increasing atheroma instability, leading to plaque rupture and clinical events. Inflammation plays a key role in the prog...
Autores principales: | Arnott, Clare, Punnia-Moorthy, Gaya, Tan, Joanne, Sadeghipour, Sara, Bursill, Christina, Patel, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784900/ https://www.ncbi.nlm.nih.gov/pubmed/26959822 http://dx.doi.org/10.1371/journal.pone.0150688 |
Ejemplares similares
-
Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017) -
CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018) -
Vascular stiffening and endothelial dysfunction in atherosclerosis
por: Hooglugt, Aukie, et al.
Publicado: (2022) -
Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
por: de Lima Farah, Julia, et al.
Publicado: (2018) -
Endothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis
por: Chen, Pei-Yu, et al.
Publicado: (2020)